Liplasome Pharma A/s

Liplasome Pharma Aps

Kent Jørgensen

Ole G Mouritsen

Jesper Davidsen

Charlotte Vermehren

Jonas Rosager Henriksen

Sune Allan Petersen

Anders Falk Vikbjerg

Fredrik Melander

Sven Frøkjer

Sven Frøkjær

The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.

Liposomes for drug delivery and methods for preparation thereof

The invention relates to targeting of diagnostic agents by use of lipid-based compositions. The invention is useful in the diagnosis of various disorders which are associated with or resulting from increased levels of extracellular PLAactivity in the diseased tissue, e.g. cancer, infectious, and inflammatory conditions.

Lipid-based systems for targeting diagnostic agents

The present invention is directed to a lipid-based delivery system for administration of an active drug substance selected from lysolipid derivatives which are particularly useful in the treatment or detection of parasitic infections, especially parasitic infections which cause an elevated PLAlevel in the infected mammal. Preferred parasitic infections are infections wherein the life cycle of the parasite involves the liver and/or spleen of the infected organism.

Lipid-based drug delivery systems against parasitic infections

Growing community of inventors

Bagsværd, Denmark

Kent Jørgensen